Study title:
Schellong-G, Bramswig-J-H, Hornig-Franz-I, Schwarze-E-W, Potter-R, Wannenmacher-M.
Universitat Kinderklinik, Albert Schweitzer Str. 33, D-48149 Munster, Germany.
Hodgkin's disease in children: Combined modality treatment for stages IA, IB, and IIA.
Annals of Oncology {ANN-ONCOL}, 1994, Vol/Iss/Pg. 5/SUPPL. 2 (113-115), ISSN: 0923-7534.Schellong-G, Bramswig-J-H, Hornig-Franz-I, Schwarze-E-W, Potter-R, Wannenmacher-M.
Universitat Kinderklinik, Albert Schweitzer Str. 33, D-48149 Munster, Germany.
Hodgkin's disease in children: Combined modality treatment for stages IA, IB, and IIA.
Annals of Oncology {ANN-ONCOL}, 1994, Vol/Iss/Pg. 5/SUPPL. 2 (113-115), ISSN: 0923-7534.
Type of medicine: Medicines containing chemical active substances
|
Therapeutic area: Neoplasms [C04]
|
Brands: Please see report |
MAH holders: Please see report |
Assessment: |
Active substance: PROCARBAZINE |
ATC code: |
Document link:
|
Document date:
|
Study number: |
EudraCT number:
|
Scope of study: Clinical |
Population of study subjects:
|
Preterm newborn Infants
|
Newborn infants
(1 to 27 days)
|
Infants and toddlers
(28 days to 24 months)
|
Children
(2 to 11 years)
|
Adolescents
(12 to 18 years)
|
|
-
|
-
|
-
|
Y
|
-
|